Low Rank Matrix Factorization Algorithm Based on Multi-Graph Regularization for Detecting Drug-Disease Association

被引:21
作者
Ai, Chengwei [1 ]
Yang, Hongpeng [2 ]
Ding, Yijie [3 ]
Tang, Jijun [4 ]
Guo, Fei [1 ]
机构
[1] Cent South Univ, Sch Comp Sci & Engn, Changsha 410083, Hunan, Peoples R China
[2] Univ South Carolina, Computat Sci & Engn, Columbia, SC 29208 USA
[3] Hainan Normal Univ, Key Lab Computat Sci & Applicat Hainan Prov, Haikou 571158, Hainan, Peoples R China
[4] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Drug-disease association; low-rank matrix factorization; multi-graph regularization; laplacian; PREDICTION;
D O I
10.1109/TCBB.2023.3274587
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Detecting potential associations between drugs and diseases plays an indispensable role in drug development, which has also become a research hotspot in recent years. Compared with traditional methods, some computational approaches have the advantages of fast speed and low cost, which greatly accelerate the progress of predicting the drug-disease association. In this study, we propose a novel similarity-based method of low-rank matrix decomposition based on multi-graph regularization. On the basis of low-rank matrix factorization with L-2 regularization, the multi-graph regularization constraint is constructed by combining a variety of similarity matrices from drugs and diseases respectively. In the experiments, we analyze the difference in the combination of different similarities, resulting that combining all the similarity information on drug space is unnecessary, and only a part of the similarity information can achieve the desired performance. Then our method is compared with other existing models on three data sets (Fdataset, Cdataset and LRSSLdataset) and have a good advantage in the evaluation measurement of AUPR. Besides, a case study experiment is conducted and showing that the superior ability for predicting the potential disease-related drugs of our model. Finally, we compare our model with some methods on six real world datasets, and our model has a good performance in detecting real world data.
引用
收藏
页码:3033 / 3043
页数:11
相关论文
共 48 条
  • [1] Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach
    Acharya, Chayan
    Coop, Andrew
    Polli, James E.
    MacKerell, Alexander D., Jr.
    [J]. CURRENT COMPUTER-AIDED DRUG DESIGN, 2011, 7 (01) : 10 - 22
  • [2] Drug repositioning: Identifying and developing new uses for existing drugs
    Ashburn, TT
    Thor, KB
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
  • [3] Belkin M, 2006, J MACH LEARN RES, V7, P2399
  • [4] A phenome-guided drug repositioning through a latent variable model
    Bisgin, Halil
    Liu, Zhichao
    Fang, Hong
    Kelly, Reagan
    Xu, Xiaowei
    Tong, Weida
    [J]. BMC BIOINFORMATICS, 2014, 15
  • [5] The Comparative Toxicogenomics Database: update 2019
    Davis, Allan Peter
    Grondin, Cynthia J.
    Johnson, Robin J.
    Sciaky, Daniela
    McMorran, Roy
    Wiegers, Jolene
    Wiegers, Thomas C.
    Mattingly, Carolyn J.
    [J]. NUCLEIC ACIDS RESEARCH, 2019, 47 (D1) : D948 - D954
  • [6] Davis J., 2006, P 23 INT C MACH LEAR, P233, DOI 10.1145/1143844.1143874
  • [7] Drug-Target Interaction Prediction with Graph Regularized Matrix Factorization
    Ezzat, Ali
    Zhao, Peilin
    Wu, Min
    Li, Xiao-Li
    Kwoh, Chee-Keong
    [J]. IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS, 2017, 14 (03) : 646 - 656
  • [8] Gonen M., 2013, International Conference on Machine Learning, P864
  • [9] PREDICT: a method for inferring novel drug indications with application to personalized medicine
    Gottlieb, Assaf
    Stein, Gideon Y.
    Ruppin, Eytan
    Sharan, Roded
    [J]. MOLECULAR SYSTEMS BIOLOGY, 2011, 7
  • [10] Computational Drug Repositioning: From Data to Therapeutics
    Hurle, M. R.
    Yang, L.
    Xie, Q.
    Rajpal, D. K.
    Sanseau, P.
    Agarwal, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) : 335 - 341